Margaret G. McGlynn is President and CEO of the International AIDS Vaccine Initiative (IAVI), a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Margaret is an experienced biopharmaceutical executive with significant expertise in the vaccine and antiretroviral markets. She retired from Merck in 2009 after 26 years with the company. Her most recent role was President, Global Vaccines and Anti-Infectives, where she was responsible for a US$7 billion portfolio of products. In addition, she was very involved in global health, and she launched several initiatives to provide access for Merck vaccines and HIV therapies in the developing world. She also served on the board and executive committee of The GAVI Alliance, a public-private partnership to bring life-saving vaccines against common infectious diseases to people across the developing world, and she played a major role in the formation of the Hilleman Center, a research center focused on developing new vaccines for the developing world, via a partnership between Merck and the Wellcome Trust.
Alex Coutinho is currently the executive director of the Infectious Diseases Institute in Kampala, Uganda. From 2001-2007 he was director of the AIDS Support Organization TASO—the largest HIV care and treatment organization in Africa. A medical doctor, Alex has been involved in the fight against HIV since the earliest cases were detected in Uganda in 1982. During his 25 year career he has been at the forefront of HIV prevention, care and treatment programs in Uganda and Swaziland. He has served as the vice chair of the Technical Review Panel of The Global Fund to Fight AIDS, Tuberculosis and Malaria and currently chairs the board of the International Partnership for Microbicides. He serves on several HIV-related Boards in Uganda.
John D. Evans is an internationally recognized expert on telecommunications and a leader in the area of technological innovation, in part as an advisor to the board of Internet2, a consortium of 202 US research universities. He has consulted and spoken extensively on the future of new technology and its impact on media and society. He is currently chairman and CEO of Evans Telecommunications Co., an investment, consulting and operating company focused on the cable television and telecommunications industries. He is one of the co-founders of C-SPAN television and served as its chairman in the early 1990s. John's interest in the application of technology to medical problems has led him to an interest in issues related to HIV and AIDS. In 1995, he was appointed by Robert Gallo, co-discoverer of HIV, to the advisory board for the Institute of Human Virology at the University of Maryland. In 1998, he was the keynote speaker for Gallo's annual meeting on AIDS and viruses, attended by more than 1000 of the world's top AIDS researchers and clinicians. In 1999, he was asked to head up a four-university research alliance, The Waterford Project, which sought to accelerate the development of an AIDS vaccine for the world. In December 2001, he received the League of African American Women's annual award for his and The Waterford Project's contributions to fighting the global AIDS pandemic. As founder of the John D. Evans Foundation, John is committed to supporting research for the battle against AIDS and cancer, protecting the environment and improving the quality of life through technological innovation, education and the arts. He graduated from the University of Michigan in 1966 and is an active alumnus of his alma mater.
Michel Greco has had a long and successful career in the pharmaceuticals and vaccines industry. From 1988 to 1993, through successive mergers and acquisitions, he had senior management responsibilities at Institut Mérieux, then Pasteur Mérieux Connaught. From 1994 to 1998, he was president and chief executive officer of Pasteur Mérieux MSD, a European joint venture between Pasteur Mérieux and Merck. From 1998 up until the beginning of 2003, he was president and chief operating officer, then deputy chief executive officer and a member of the board, of Aventis Pasteur. Michel was president of the European Vaccine Manufacturers between 1994 and 1998. From 1999 to 2002, he was chairman of the biological committee of the International Federation of Pharmaceutical Manufacturers Associations and a member of the Strategic Advisory Group of Experts, which advises the World Health Organization on immunization policy. He is presently a member of the boards of a number of biotechnology companies and of nonprofit international organizations. He has communicated in various industry journals over the years and published several articles on the vaccine industry.
Ian Gust is currently a professorial fellow in the Department of Microbiology and Immunology at the University of Melbourne. By training a medical virologist, Ian studied at the University of Melbourne and did postgraduate work at The London School of Hygiene and Tropical Medicine, the University of Glasgow and the US National Institutes of Health. His career has bridged the public and private sectors, initially as the director of The McFarlane Burnet Centre for Medical Research, then as director of research and development at CSL Ltd, a major manufacturer of vaccines and other biologicals. He has a major interest in international public health, having directed four World Health Organization Collaborating Centres and served as a foundation member of the International Task Force for Hepatitis Immunization and as the Australian government's principal advisor on the medical and scientific aspects of AIDS. Ian has been involved in the development of several licensed vaccines and is the author of three books, more than 300 publications and a number of patents.
Paul Klingenstein has been a health-care technology venture capital investor for most of his professional career. Beginning at Warburg, Pincus in the early 1980s, he joined Accel Partners in 1986 and helped, through the next decade, to build a leading venture capital firm. After a brief period as an advisor to the Rockefeller Foundation, he formed Aberdare Ventures in 1999. Paul has been an active participant in more than 50 companies, the majority of which are now public, or have been merged into public companies. These investments comprise mostly early-stage domestic businesses, but also include later-stage, public, and non-U.S. companies. His current and former boards include Alibris, Ample Medical, Anacor Pharmaceuticals, Aviron, Conatus Pharmaceuticals, EP Technologies, Idun Pharmaceuticals, Isis Pharmaceuticals, Posit Science, Pharmion, Salmedix, US Behavioral Health, VertiFlex and Xomed Surgical Products. In the late 1990s, Paul advised on private sector healthcare initiatives in India, China, and Malaysia; in the late 1970s he worked as a field biologist in Tanzania, Kenya, and Uganda. He has served on the boards of various educational and nonprofit institutions including the African Wildlife Foundation, Juma Ventures, the Marin Country Day School, and The Taft School. He received an AB from Harvard and an MBA from Stanford.
Reinhard Kurth was Director of the Robert Koch Institute in Berlin from October 1996 to February 2008. From 2004 to 2007 he held the post of Acting Head of the Federal Institute for Drugs and Medical Devices in Bonn. Before moving to Berlin, he was, from 1986 until 1999, Director of the Paul Ehrlich Institute in Langen. All three Federal Institutes are involved in basic, applied and commissioned research relevant to public health. A virologist and physician, Dr. Kurth's scientific work is focused on retroviruses and their interactions with animals and humans. He has published more than 350 peer-reviewed scientific articles. In 1998 he was appointed a member of the Berlin-Brandenburg Academy of Sciences and in 2005 he was made a member of the American Philosophical Society. Also in 2005, he was awarded the Commander’s Cross of the Order of Merit of the Federal Republic of Germany for his exceptional service in virology and immunology and for his successful development of the three major Federal Institutes of which he has been director. He was awarded an honorary doctorate by Humboldt University and the Free University in Berlin in 2006. In 2008 he was appointed a member of the German Academy of Sciences Leopoldina and in 2009 he became the first Robert Koch Fellow of the Robert Koch Institute.
An Irish national born in South Africa, Geoff Lamb has held several senior development positions, most recently as vice president, Concessional Finance and Global Partnerships at the World Bank. In that capacity, he chaired a series of international negotiations through which governments provided the largest increase in more than two decades of World Bank funding for the world's poorest countries, and subsequently agreed on the financial framework to forgive the multilateral debt owed by 40 of these countries. Previously, in his academic career, he served as fellow and deputy director of the Institute of Development Studies at Sussex. Geoff has worked extensively in countries in Asia, Africa, Europe, the former Soviet Union, and the Middle East. Lamb was a founding member of the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria.
A 20-year veteran of the recruitment business, Mary Tydings currently serves as the not-for-profit global sector leader and leads the Washington, D. C. office at Russell Reynolds Associates. In this role, she works with major national and international foundations, non-governmental organizations and cultural institutions to recruit chief executives and to advise directors on issues of governance, succession planning, executive transition and board development. Mary has received the firm's highest honor, the President's Award, which recognizes those of the highest caliber who embodied the firm's values by focusing on teamwork, serving as a role model and nurturing a collaborative culture. She began her career in journalism, spending several years as a reporter and editor for the Mutual Broadcasting System before joining the Larry King Show as a producer in1981, where she won a prestigious Peabody Award. She also worked in the White House during the Clinton administration in the Office of Presidential Personnel from 1992-1993. Mary is an active director of the Joseph Davies Foundation, having served as Board President from 1998-2005, is a member of the Board of the Campaign for the Prevention of Teen and Unplanned Pregnancy, and is a former member of the Board of the School of Public Policy at the University of Maryland.
Helen Rees is the founder and Executive Director of the Wits Institute for Sexual & Reproductive Health, HIV and Related Diseases of the University of the Witwatersrand, where she is an Ad Hominem Professor in the Department of Obstetrics and Gynecology. She received a medical degree and a master's in social and political sciences from Cambridge University, and in 2002 became an alumnus of Harvard Business School. Professor Rees is co-chair of South Africa’s National AIDS Council’s Programme Implementing Committee and a member of the National Advisory Group on Immunizations. She served as the chair of South Africa’s Medicines Control Council and was a member of the National Research Ethics Committee. She has a research interest in HIV/AIDS prevention, sexually transmitted infections, microbicides, HIV and HPV vaccines, and broader issues relating to women’s health. She is the chair of the World Health Organization’s Strategic Advisory Group of Experts on Immunization and serves on the HIV Vaccine Advisory Committee and the HPV Vaccine Expert Committee. She serves on international committees of many international organizations, including the U.S. National Institutes of Health, The GAVI Alliance and the Population Council. In 2001 she was made an Officer of the British Empire for her contribution to global health. In 2004 she became the first woman to be awarded the South African Distinguished Scientist award for her outstanding contribution to improving the quality of life of women. In 2006 she was appointed to the South African Academy of Sciences. She was given a lifetime achievement award by Amanitare, a pan-African organization dedicated to the rights of African women and children. In 2009 she was made an Honorary Professor at the London School of Hygiene and Tropical Medicine, which also awarded her the prestigious international Heath Clark Lectureship for 2010.
Anne VanLent has served the emerging growth life sciences industry in senior finance and executive management roles for 25 years, and is currently President of AMV Advisors, providing strategy and financial management services to the industry. From 2002 until mid-2008 she served as executive vice president and chief financial officer for Barrier Therapeutics, Inc. (NASDAQ: BTRX) where she managed the finance, treasury, human resources, information technology and investor relations functions. Throughout her career in life sciences, she has been involved in the public and private financing, accounting oversight, and portfolio management of research and development driven organizations. She served as EVP of portfolio management for Sarnoff Corporation from 1997 to 2001, overseeing the patent and licensing function and new venture creation for the Sarnoff Corporation, a multi-disciplinary research and development organization. Her interest in today's global health challenges, particularly AIDS, is an outgrowth of her experience in the industry, interest in the plight of women and children lacking adequate access to healthcare, and her scientific background. Anne is currently a member of the board of directors and chair of the audit committee for two publicly-traded companies: Integra Life Sciences Holdings Corporation (NASDAQ:IART) and Penwest Pharmaceutical Corporation (NASDAQ: PPCO). She is a member of two other not-for-profit boards and is involved in microfinance. Anne received a BA in physics from Mount Holyoke College and did graduate work in biophysics.
Marijke Wijnroks was appointed the Netherlands' HIV/AIDS Ambassador on July 1, 2009. She has worked at the Netherlands' Ministry of Foreign Affairs since 1998, previously serving as Senior Advisor on Health and HIV/AIDS. In this position, she represented the Netherlands in the Global Fund to Fight Aids, Tuberculosis and Malaria. Marijke is a qualified physician who has been involved in the global fight against HIV/AIDS and other health issues for decades. Before joining the ministry, she worked for the Pan American Health Organization in El Salvador (1993-1998), Helen Keller International in Bangladesh (1991-1993) and Médecins Sans Frontières in Southern Sudan and Uganda (1987-1991).
Board of Directors, Emeritus
Michèle Barzach, MD
Health Strategy Consultant & Advisor, Michèle Barzach Santé
Former Minister of Health, France
Awa Marie Coll-Seck, MD, PhD
Executive Secretary, Roll Back Malaria Partnership
Former Minister of Health and Prevention, Senegal
R. Gordon Douglas, Jr, MD
Consultant, Vaccines, Infectious Diseases & Global Health
Former President, Merck Vaccines Division, Merck and Co. Inc.
Richard G. A. Feachem, KBE, FREng, DSc (Med), PhD (Former Treasurer)
Professor of Global Health, University of California, San Francisco
Former Executive Director, Global Fund to Fight AIDS, Tuberculosis and Malaria
Hilde Frafjord Johnson
Deputy Executive Director, United Nations Children's Fund
Former Minister of International Development, Norway
Angela Gómez de Mogollón
President, Profamilia;
former President, International Planned Parenthood
Jaap Goudsmit, MD, PhD (Founding Chair, Scientific Advisory Committee)
Chief Scientific Officer, Member of the Management Board, Crucell NV
Co-Founder, European Vaccine Effort Against HIV/AIDS
Geeta Rao Gupta, PhD (Former Chair, Board Nominating Committee)
Deputy Executive Director, United Nations Children's Fund
Former President, International Center for Research on Women
Michel Kazatchkine, MD
Executive Director, The Global Fund to Fight AIDS,
Tuberculosis and Malaria
Glenys Kinnock
Member of the European Parliament
Chrispus Kiyonga, MD
Minister of Defense, Government of the Republic of Uganda
Former Minister Without Portfolio, Uganda Former Minister of Health, Uganda
Stephen Lewis
Co-Director, AIDS-Free World
Former United Nations Envoy for HIV/AIDS in Africa
Julian Lob-Levyt, MBChB, DRCOG
Managing Director, DAI Europe
Former Executive Secretary, GAVI Secretariat
Malegapuru William Makgoba, MBChB, DPhil, FRCP
Vice-Chancellor & Principal, University of KwaZulu-Natal
Former President, Medical Research Council, South Africa
Jacques-François Martin
President Parteurop
Former President, The Vaccine Fund
Former Chief Executive Officer, Pasteur Mérieux MSD
Peter Piot, MD, PhD
Director, Institute for Global Health, Imperial College
Philip K. Russell, MD (Former Secretary)
Professor Emeritus, Johns Hopkins School of Public Health
Former Principal Science Advisor, Vaccine Development, U.S. Department of Health and Human Services
Kapil Sibal, JD
Minister of Human Resource Development
Minister of Communications and Information Technology
Government of India
Lee C. Smith (Founding Chair)
Former President, Levi Strauss International
Former Chair, US National Leadership on AIDS
Richard Sykes, DSc, FRS, FMedSci
Rector Imperial College London
Former Chair and Chief Executive Officer, GlaxoSmithKline plc
Shudo Yamazaki, MD, PhD
Director-General Emeritus, National Institute of Infectious Diseases, Japan
Ciro de Quadros, MD, MPH
Executive Vice President Albert B. Sabin Vaccine Institute
Former Director, Vaccines and Immunization, Pan American Health Organization